Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626626 · ClinicalTrials.gov registry record · Phase 1
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
A Phase 1 study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00626626 is a Phase 1 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 8 participants.
The verdict
NCT00626626, a Phase 1 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Allogeneic hematopoietic transplant is curative for many patients with hematological neoplasms but conditions to provide optimal engraftment and anti-tumor efficacy with minimal toxicity are still under way. Clofarabine is a newly licensed agent with dramatic anti-leukemic activity. Its incorporation into a regimen for pre-transplant conditioning of acute leukemia and lymphoma patients is logical, exploiting both the anti-tumor activities it is recognized to have and the immunosuppressive activity seen with drugs in its class.
Interventions
- DRUG Clofar, Cyclophos, Alemtuzumab
- DRUG Clofar, Cyclophos,Alemtuzumab(Ph II)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626626
The ClinicalTrials.gov registry entry for NCT00626626 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clofar, Cyclophos, Alemtuzumab is the first listed.
NCT00626626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00626626 about?
NCT00626626 is a clinical study titled "Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation". Allogeneic hematopoietic transplant is curative for many patients with hematological neoplasms but conditions to provide optimal engraftment and anti-tumor efficacy with minimal toxicity are still under way. Clofarabine is a newly licensed agent with dramatic anti-leukemic activity. Its incorporatio...
What is the current status of trial NCT00626626?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2007-05. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00626626?
The interventions under investigation include: Clofar, Cyclophos, Alemtuzumab (DRUG), Clofar, Cyclophos,Alemtuzumab(Ph II) (DRUG).
Who is sponsoring clinical trial NCT00626626?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.